How to study- infographs
[…]
Read More[…]
Read MoreDiagnosing bipolar disorder Many patients with borderline personality disorder or other forms of moodiness are wrongly diagnosed as having bipolar disorder. On the other hand, it is simultaneously true that many patients with bipolar disorder (especially bipolar II disorder) continue to be misdiagnosed as having a […]
Read More(If you are not already signed up for FREE tips, news, and updates from this website, please enter your email address at the bottom of this page. Don’t miss out on this opportunity!) The US medical system switched from ICD-9-CM to ICD-10-CM on October 1, 2015. […]
Read MoreTo screen for Obstructive Sleep Apnea, we need to check for multiple factors. The STOP-Bang questionnaire looks at these multiple factors. A link to information about the questionnaire is provided below. 1. Snoring Ask the patient and the person who sleeps […]
Read MoreOlanzapine (US brand name Zyprexa® and generic) is a second-generation (atypical) antipsychotic. Here is basic information about this medication. FDA-approved indications 1. As oral formulation for: a. Schizophrenia in adults and adolescents b. Manic or mixed episodes associated with bipolar I disorder in adults and adolescents […]
Read MorePaliperidone extended-release (US brand name Invega® and generic) is a second-generation (“atypical”) antipsychotic. FDA-approved indications 1. Treatment of schizophrenia in adults and adolescents (ages 12-17) 2. Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Dosage A. Schizophrenia […]
Read MorePaliperidone palmitate (Invega Trinza®) is an extended-release injectable second-generation (“atypical”) antipsychotic which can be administered once every 3 months. Here is basic information about this medication. FDA-Approved Indication Schizophrenia after adequate treatment with 1-month paliperidone palmitate extended-release (Invega Sustenna®) for at least four months. Dosage The dose of 3-month […]
Read MorePaliperidone palmitate (Invega Sustenna®) is an extended-release injectable second-generation (“atypical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenia Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants Dosage A. Schizophrenia Initiation (IM deltoid): Administer 234 mg […]
Read MoreExtended Release Olanzapine (Zyprexa Relprevv®) is a long-acting, second-generation (atypical), injectable antipsychotic. Here is basic information about this medication. FDA-approved indications Schizophrenia Dosage Recommended dosing of extended release olanzapine based on correspondence to oral olanzapine doses A. First 8 weeks of treatment a) Target oral dose 10 mg/day: 210 […]
Read MoreHaldol® Decanoate is a brand name of a depot formulation of haloperidol which is a first-generation (“typical”) antipsychotic. Here is basic information about this medication. FDA-approved indications Treatment of schizophrenic patients who require prolonged parenteral antipsychotic therapy Dosage A. Initial dosage (given by deep IM injection […]
Read More